Heated belly chemo plus niraparib after interval surgery for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 3 study tests whether heated chemotherapy placed inside the belly, followed by interval surgery and the maintenance medicine niraparib, can improve outcomes for certain advanced ovarian, fallopian tube, or primary peritoneal cancers. It focuses on people whose tumors are HRD/LOH positive and who can have all visible disease removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, and it is FIGO stage III or IV.
- Your cancer plan includes 3–4 cycles of platinum chemotherapy (with or without bevacizumab) and then interval cytoreductive surgery (ICRS) followed by chemotherapy and niraparib maintenance.
- Your tumor test shows HRD/LOH positive (and you must have the test result available before enrollment).
- After surgery, there is no visible disease (R0) or only a very small amount left (R1, ≤1.0 cm).
- Your blood counts and organ function are strong enough (for example, hemoglobin ≥ 8.5, ANC ≥ 1500, platelets ≥ 100,000; kidney and liver tests within limits).
- You are age over 18, can do daily activities fairly normally (ECOG 0–1), and are expected to live more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a different starting dose (and adjustments) of niraparib can help people with advanced ovarian (or related) cancer stay on treatment without as many dose interruptions. It’s designed for people who have already finished first-line chemotherapy and whose cancer responded.
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
This trial tests whether niraparib, taken after surgery, works better when combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have no visible tumor left. It also aims to see if this approach helps prevent the cancer from coming back.
This trial studies whether adding a special heated chemotherapy treatment during surgery (called HIPEC) improves outcomes for some people with ovarian, fallopian tube, or primary peritoneal cancer. It compares surgery alone versus surgery plus HIPEC after you’ve had chemotherapy first.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
Hear when a new Stage III Fallopian Tube Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.